Skip to main
DXCM

DexCom (DXCM) Stock Forecast & Price Target

DexCom (DXCM) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 48%
Buy 38%
Hold 10%
Sell 5%
Strong Sell 0%

Bulls say

DexCom is a global leader in the growing market of continuous glucose monitoring, with its innovative CGM devices and software facilitating better management for diabetic patients. The company boasts strong revenue growth and profitability, driven by its expanding presence in the US and OUS markets, as well as its pipeline of product enhancements. With a solid balance sheet and ongoing investments in R&D and acquisitions, DexCom is well positioned for continued success and remains a Buy.

Bears say

DexCom is facing potential challenges with incremental commercial and Medicare coverage expansion in the future, as well as concerns about its revenue seasonality and pharmacy mix going forward. It is also facing potential pressure on expenses due to the operation of a new facility in Ireland. Additionally, while the company shows promise in the growing OUS market, there are execution risks and potential for continuing to trade at a discount to peers. The recent revenue report was in line with expectations and the company continues to iterate its offerings, but there may be challenges in maintaining its status while dealing with FDA decisions and coverage for non-insulin Type 2 patients. Though the company has an upcoming RCT and investor day, the current PT reflects a discounted value in comparison to similar companies.

DexCom (DXCM) has been analyzed by 21 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 38% recommend Buy, 10% suggest Holding, 5% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of DexCom and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About DexCom (DXCM) Forecast

Analysts have given DexCom (DXCM) a Buy based on their latest research and market trends.

According to 21 analysts, DexCom (DXCM) has a Buy consensus rating as of May 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $84.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $84.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

DexCom (DXCM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.